The experimental therapy M102 slowed disease progression in preclinical experiments done in mouse and cell models of ALS, a ...
Transition Bio and Voyager have teamed to discover and develop new small molecules that target toxic TDP-43 protein clumps in ...
The ALS prevalence is expected to rise across multiple nations by 2040 due to aging populations and increased ALS survival ...
Teaming up with the Healey & AMG Center, Inflammasome will advance its oral ALS drug kamuvudine-9, known as K9, into early clinical testing.
Columnist Juliet Taylor discusses the Tim Lowrey ALS Panel Series, which has provided tailored information to 1,500 people ...
Oprah's interview with Emma Heming Willis resonated with columnist Kristin Neva, who reflects on life as an ALS caregiver.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback